An open label Positron Emission Tomography (PET) study to determine central mGluR5 receptor occupancy of AZD2516

Study identifier:D2080C00009

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

An open label Positron Emission Tomography (PET) study with [11C]AZ12713580 to determine central mGluR5 receptor occupancy of AZD2516 after oral administration to healthy subjects

Medical condition

Healthy

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD2516

Sex

All

Actual Enrollment

Study type

Interventional

Age

20 Years - 45 Years

Date

Study Start Date: 01 Apr 2009

Primary Completion Date: -

Study Completion Date: 01 Oct 2009

Study design

Allocation: N/A
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions
Experimental: 1 AZD2516	Drug: AZD2516 Fractionated single oral dose

Documents available

https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=1240&filename=CSR-D2080C00009.pdf
Download
CSR-D2080C00009.pdf
Download
Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Clinical Study Information

: 800-236-9933

[email protected]

Contact Backup

AstraZeneca Information, (Outside US)

001-800-236-9933

Investigators

Principal Investigator

Ingemar Bylesjo

AstraZeneca Clinical Pharmacology Unit, Stockholm, Sweden